Corcept Therapeutics
CORT
CORT
225 hedge funds and large institutions have $2.02B invested in Corcept Therapeutics in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 75 increasing their positions, 90 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
1% less funds holding
Funds holding: 228 → 225 (-3)
17% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 90
27% less call options, than puts
Call options by funds: $4.45M | Put options by funds: $6.06M
Holders
225
Holding in Top 10
3
Calls
$4.45M
Puts
$6.06M
Top Buyers
| 1 | +$60.1M | |
| 2 | +$18.9M | |
| 3 | +$18.4M | |
| 4 |
D.E. Shaw & Co
New York
|
+$11.7M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$6.05M |
Top Sellers
| 1 | -$27.4M | |
| 2 | -$16.2M | |
| 3 | -$13.4M | |
| 4 |
Man Group
London,
United Kingdom
|
-$10M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.01M |